{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:30:20Z","timestamp":1779910220331,"version":"3.53.1"},"reference-count":17,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Consejer\u00eda de Salud, Junta de Andaluc\u00eda"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,4,15]]},"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The Janus kinase and Signal Transducer and Activator of Transcription protein (JAK\/STAT) pathway is known to be involved in inflammatory and neoplastic skin diseases, like psoriasis, atopic dermatitis, alopecia areata, vitiligo and melanoma. Improved knowledge of the components of this pathway has allowed the development of drugs, which act by inhibiting the pathway, blocking specific components. This offers new therapeutic opportunities. Although evidence on the use of JAK\/STAT blockades in dermatological diseases is growing, none have been approved for use in treating skin diseases. The aim of this study is to develop an a priori protocol to broadly review the available evidence on the use of drugs targeting the JAK\/STAT pathway in the treatment of dermatological diseases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>For the conduction of the scoping review protocol, we will employ an established scoping review methodology described in the Joanna Briggs Institute manual. This methodology outlines a five-stage approach: (1) identify the research question; (2) identify relevant studies; (3) select studies; (4) chart the data and (5) collate, summarise and report the results, with an optional consultation exercise. Finally, we will use the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews to present the results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>Since this is a review of the literature, ethics approval is not indicated. We will disseminate the findings from this study in publications in peer-reviewed journals as well as presentations at relevant national and international conferences.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-028303","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T08:41:17Z","timestamp":1558600877000},"page":"e028303","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Drugs targeting the JAK\/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review"],"prefix":"10.1136","volume":"9","author":[{"given":"Francisco","family":"G\u00f3mez-Garc\u00eda","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Reina Sofia, Cordoba, Spain"},{"name":"Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)\/Hospital Universitario Reina Sof\u00eda\/Universidad de Cordoba, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Jes\u00fas","family":"G\u00f3mez-Arias","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Reina Sofia, Cordoba, Spain"},{"name":"Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)\/Hospital Universitario Reina Sof\u00eda\/Universidad de Cordoba, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital Universitario Reina Sofia, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Montilla","sequence":"additional","affiliation":[{"name":"Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)\/Hospital Universitario Reina Sof\u00eda\/Universidad de Cordoba, Cordoba, Spain"},{"name":"University of Cordoba, School of Medicine, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Gay-Mimbrera","sequence":"additional","affiliation":[{"name":"Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)\/Hospital Universitario Reina Sof\u00eda\/Universidad de Cordoba, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Aguilar-Luque","sequence":"additional","affiliation":[{"name":"Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)\/Hospital Universitario Reina Sof\u00eda\/Universidad de Cordoba, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Viguera-Guerra","sequence":"additional","affiliation":[{"name":"Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)\/Hospital Universitario Reina Sof\u00eda\/Universidad de Cordoba, Cordoba, Spain"},{"name":"Agencia de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias (AETSA), Consejer\u00eda de Salud, Junta de Andaluc\u00eda, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Velez Garc\u00eda-Nieto","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Reina Sofia, Cordoba, Spain"},{"name":"Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)\/Hospital Universitario Reina Sof\u00eda\/Universidad de Cordoba, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Isla-Tejera","sequence":"additional","affiliation":[{"name":"Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)\/Hospital Universitario Reina Sof\u00eda\/Universidad de Cordoba, Cordoba, Spain"},{"name":"Department of Pharmacy, Hospital Universitario Reina Sofia, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0286-4107","authenticated-orcid":false,"given":"Juan","family":"Ruano","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Reina Sofia, Cordoba, Spain"},{"name":"Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)\/Hospital Universitario Reina Sof\u00eda\/Universidad de Cordoba, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"2025101813193463000_9.5.e028303.1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00963"},{"key":"2025101813193463000_9.5.e028303.2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/09546634.2016.1277179","article-title":"Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature","volume":"28","author":"Samadi","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"2025101813193463000_9.5.e028303.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.12.024"},{"key":"2025101813193463000_9.5.e028303.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.167"},{"key":"2025101813193463000_9.5.e028303.5","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025101813193463000_9.5.e028303.6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003668"},{"key":"2025101813193463000_9.5.e028303.7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/ced.12273","article-title":"An insight into JAK-STAT signalling in dermatology","volume":"39","author":"Palanivel","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"2025101813193463000_9.5.e028303.8","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/eji.201646680","article-title":"Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors","volume":"47","author":"Welsch","year":"2017","journal-title":"Eur J Immunol"},{"key":"2025101813193463000_9.5.e028303.9","unstructured":"INCYTE. FDA Approves Incyte\u2019s Jakafi(TM) (ruxolitinib) for Patients with Myelofibrosis. https:\/\/investor.incyte.com\/news-releases\/news-release-details\/fda-approves-incytes-jakafitm-ruxolitinib-patients-myelofibrosis."},{"key":"2025101813193463000_9.5.e028303.10","doi-asserted-by":"publisher","DOI":"10.2146\/news120088"},{"key":"2025101813193463000_9.5.e028303.11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2016.12.004","article-title":"Janus kinase inhibitors in dermatology: A systematic review","volume":"76","author":"Shreberk-Hassidim","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025101813193463000_9.5.e028303.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.03.013"},{"key":"2025101813193463000_9.5.e028303.13","unstructured":"The Joanna Briggs Institute. The Joanna Briggs Institute reviewer\u2019s manual. 2015 http:\/\/joannabriggs.org\/assets\/docs\/sumari\/Reviewers-Manual_Methodology-for-JBI-Scoping-Reviews_2015_v2.pdf (Sept 29 2016)."},{"key":"2025101813193463000_9.5.e028303.14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"2025101813193463000_9.5.e028303.15","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2004-5-12-253"},{"key":"2025101813193463000_9.5.e028303.16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537"},{"key":"2025101813193463000_9.5.e028303.17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13643-015-0163-7","article-title":"All in the family: systematic reviews, rapid reviews, scoping reviews, realist reviews, and more","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-028303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:19:44Z","timestamp":1760818784000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-028303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":17,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,22]]},"published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1136\/bmjopen-2018-028303"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-028303","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}